samantha robertson - nhmrc - improving the australian clinical trials environment
TRANSCRIPT
![Page 1: Samantha Robertson - NHMRC - Improving the Australian Clinical Trials Environment](https://reader033.vdocuments.net/reader033/viewer/2022051502/58f037431a28ab764d8b45dd/html5/thumbnails/1.jpg)
Improving the Australian Clinical Trials Environment
Samantha Robertson
Executive Director
Evidence, Advice and Governance Branch
![Page 2: Samantha Robertson - NHMRC - Improving the Australian Clinical Trials Environment](https://reader033.vdocuments.net/reader033/viewer/2022051502/58f037431a28ab764d8b45dd/html5/thumbnails/2.jpg)
• Setting the scene for Clinical Trials Reforms
• Barriers to reform – Legal or Cultural?
• Many reforms – not all regulatory
• The Good Practice Process
Overview
![Page 3: Samantha Robertson - NHMRC - Improving the Australian Clinical Trials Environment](https://reader033.vdocuments.net/reader033/viewer/2022051502/58f037431a28ab764d8b45dd/html5/thumbnails/3.jpg)
1. Each year approx. $6b is invested in health R&D in Australia
– Approximately 0.4% of GDP
– 20% is in the private sector (mostly pharmaceutical R&D)
2. $1.3b is funding from the Australian Government
3. Governments are the majority funders of our public health system
Why is Government interested?
![Page 4: Samantha Robertson - NHMRC - Improving the Australian Clinical Trials Environment](https://reader033.vdocuments.net/reader033/viewer/2022051502/58f037431a28ab764d8b45dd/html5/thumbnails/4.jpg)
• Three reports over seven years– Pharmaceuticals Industry Strategy Group 2009
– Clinical Trials Action Group 2010
– McKeon review – April 2013
• Budget measures– 2013-14 - $9.9m over 5 years – A Plan for Australian
Jobs: Clinical Trials Reform in Australia
– 2014-15 - $9.9m over 5 years – Simplified and Consistent Health and Medical Research
Why Clinical Trials Reform?
![Page 5: Samantha Robertson - NHMRC - Improving the Australian Clinical Trials Environment](https://reader033.vdocuments.net/reader033/viewer/2022051502/58f037431a28ab764d8b45dd/html5/thumbnails/5.jpg)
Commonwealth
Industry
States
Territories
&
Peak bodies (MA/MTAA)
CT Networks
Sector complexity
Universities/ MRIs
Public hospitals Private/Catholic Hospitals
Patients
![Page 6: Samantha Robertson - NHMRC - Improving the Australian Clinical Trials Environment](https://reader033.vdocuments.net/reader033/viewer/2022051502/58f037431a28ab764d8b45dd/html5/thumbnails/6.jpg)
• Funding body
• Standard setter
• Guideline developer
• Ethics advice
• Clinical trials
• Research translation…the list goes on…….
What is NHMRC and why is it involved in clinical trials?
6
![Page 7: Samantha Robertson - NHMRC - Improving the Australian Clinical Trials Environment](https://reader033.vdocuments.net/reader033/viewer/2022051502/58f037431a28ab764d8b45dd/html5/thumbnails/7.jpg)
Australia’s end game?
7
Preferentially selected as a destination to conduct trials due to:
• Cost• Timeliness• Quality• Recruitment efficiency
But, there is much more to it than that…
![Page 8: Samantha Robertson - NHMRC - Improving the Australian Clinical Trials Environment](https://reader033.vdocuments.net/reader033/viewer/2022051502/58f037431a28ab764d8b45dd/html5/thumbnails/8.jpg)
• Patient centred model
• Evidence-(data)-based policy development
• Recognise the existing structures that can help us translate research
• Working together
Other important aspects to consider
8
![Page 9: Samantha Robertson - NHMRC - Improving the Australian Clinical Trials Environment](https://reader033.vdocuments.net/reader033/viewer/2022051502/58f037431a28ab764d8b45dd/html5/thumbnails/9.jpg)
Clinical Trials Jurisdictional Working Group
– All states and territories
– Large reform agenda:
1. Establish a metrics system and promote ICT interoperability:
2. Enhance national consistency for ethics and governance:
3. Improve efficiency of recruitment and accruals:
4. Strategy for positioning Australia as a preferred location for clinical trials
A multi-jurisdictional approach
9
![Page 10: Samantha Robertson - NHMRC - Improving the Australian Clinical Trials Environment](https://reader033.vdocuments.net/reader033/viewer/2022051502/58f037431a28ab764d8b45dd/html5/thumbnails/10.jpg)
10
QUICKER AND MORE EFFICIENT RESEARCH GOVERNANCE AUTHORISATION
Australia is competitive globally and delivers clinical trials of high quality
EFFICIENT ETHICS APPROVAL
INCREASED SITE READINESS AND TRANSPARENCY
BETTER TRAINED STAFF
INCREASED PATIENT RECRUITMENT AND COMMUNITY AWARENESS
What does a strong clinical trials environment look like?
![Page 11: Samantha Robertson - NHMRC - Improving the Australian Clinical Trials Environment](https://reader033.vdocuments.net/reader033/viewer/2022051502/58f037431a28ab764d8b45dd/html5/thumbnails/11.jpg)
What do we need to make Australia competitive?
11
Quality
Transparency and Predictability
Efficiency
Collaboration
![Page 12: Samantha Robertson - NHMRC - Improving the Australian Clinical Trials Environment](https://reader033.vdocuments.net/reader033/viewer/2022051502/58f037431a28ab764d8b45dd/html5/thumbnails/12.jpg)
• Fragmented decision making and approvals
• Inconsistency in rules between jurisdictions
• Institutional culture and the power of myths
• Lack of single point of contact between institution and sponsor
Barriers to reform
![Page 13: Samantha Robertson - NHMRC - Improving the Australian Clinical Trials Environment](https://reader033.vdocuments.net/reader033/viewer/2022051502/58f037431a28ab764d8b45dd/html5/thumbnails/13.jpg)
• Quicker and more efficient ethics review and research governance authorisation:
– Good practice process for site assessment and authorisation
– Redesigned ethics application
• Better trained staff:– Learning modules for clinical trials
– Development of competencies for clinical trialists
• Increased recruitment and awareness of clinical trials
– www.AustralianClinicalTrials.gov.au
• Improved quality and transparency in clinical trials– Alignment of safety monitoring and reporting requirements
– Establishment of national scientific committees
Clinical trials work being done by NHMRC
![Page 14: Samantha Robertson - NHMRC - Improving the Australian Clinical Trials Environment](https://reader033.vdocuments.net/reader033/viewer/2022051502/58f037431a28ab764d8b45dd/html5/thumbnails/14.jpg)
![Page 15: Samantha Robertson - NHMRC - Improving the Australian Clinical Trials Environment](https://reader033.vdocuments.net/reader033/viewer/2022051502/58f037431a28ab764d8b45dd/html5/thumbnails/15.jpg)
![Page 16: Samantha Robertson - NHMRC - Improving the Australian Clinical Trials Environment](https://reader033.vdocuments.net/reader033/viewer/2022051502/58f037431a28ab764d8b45dd/html5/thumbnails/16.jpg)
• Long standing concern in sector
• Different views on what the problem is
• Myth? Law? Institutional culture? Distrust?
Addressing Barriers - Insurance and Indemnity
![Page 17: Samantha Robertson - NHMRC - Improving the Australian Clinical Trials Environment](https://reader033.vdocuments.net/reader033/viewer/2022051502/58f037431a28ab764d8b45dd/html5/thumbnails/17.jpg)
• No particular barriers, as long as the approving ethics committee is insured.
• No particular requirement that clinical trials in a public health service cannot be ethically reviewed by an external, private sector HREC….
• No insurers stipulate use of a particular HREC – public or private.
Cross jurisdictional issues regarding insurance and indemnity?
![Page 18: Samantha Robertson - NHMRC - Improving the Australian Clinical Trials Environment](https://reader033.vdocuments.net/reader033/viewer/2022051502/58f037431a28ab764d8b45dd/html5/thumbnails/18.jpg)
• Variation in laws across States and Territories
• Impacts on single ethical review…but
• …distinction between legal and ethical issues
• 2016 Review by NHMRC and upcoming Fact Sheets for HRECs
Guardianship and Consent Laws
![Page 19: Samantha Robertson - NHMRC - Improving the Australian Clinical Trials Environment](https://reader033.vdocuments.net/reader033/viewer/2022051502/58f037431a28ab764d8b45dd/html5/thumbnails/19.jpg)
• GPP developed in consultation with sponsors, researchers, institutions and other stakeholders
• Tested in a two-phase pilot:
• Phase 1 – 16 sites around Australia
• Phase 2 – 9 sites (drawn from original 16).
• GPP provides the value proposition for engagement of a CTLO
The Good Practice Process (GPP)
![Page 20: Samantha Robertson - NHMRC - Improving the Australian Clinical Trials Environment](https://reader033.vdocuments.net/reader033/viewer/2022051502/58f037431a28ab764d8b45dd/html5/thumbnails/20.jpg)
Impact of Clinical Trial Liaison Officer
20
• Collect data to improve internal processes
• Communication
• Central contact
• ‘Shepherding’ of applications
![Page 21: Samantha Robertson - NHMRC - Improving the Australian Clinical Trials Environment](https://reader033.vdocuments.net/reader033/viewer/2022051502/58f037431a28ab764d8b45dd/html5/thumbnails/21.jpg)
GPP MetricsMetric Process Phase Time period measured
1a-1d Feasibility AssessmentDate the Confidential Disclosure Agreement is sent to the Principal Investigator to the date the sponsor notifies the site of site selection.
2Document Preparation
Date the sponsor notifies the site of site selection to the date valid site assessment/ethics review documentation is submitted to the institution.
3 Ethics ReviewDate a valid ethics review application is provided to the institution to the date an ethics approval notification is provided to the (Co-ordinating) Principal Investigator.
4 Site AssessmentDate a valid site assessment application is provided to the institution to the date the site assessment is finalised.
5 Site authorisationDate a valid site assessment has been finalised to the date the site authorisation is granted by the CEO or their delegate.
6First patient recruitment
Date site authorisation is granted to the date the first participant is recruited into the clinical trial.
![Page 22: Samantha Robertson - NHMRC - Improving the Australian Clinical Trials Environment](https://reader033.vdocuments.net/reader033/viewer/2022051502/58f037431a28ab764d8b45dd/html5/thumbnails/22.jpg)
![Page 23: Samantha Robertson - NHMRC - Improving the Australian Clinical Trials Environment](https://reader033.vdocuments.net/reader033/viewer/2022051502/58f037431a28ab764d8b45dd/html5/thumbnails/23.jpg)
• Collect and advertise information on sites
• Involve sponsors and CROs in meetings with sites
• Sites having sponsor evenings
• Need to work with Medicines Australia and other Peak Bodies
Working with industry
23
![Page 24: Samantha Robertson - NHMRC - Improving the Australian Clinical Trials Environment](https://reader033.vdocuments.net/reader033/viewer/2022051502/58f037431a28ab764d8b45dd/html5/thumbnails/24.jpg)
• Many actors involvement in delivering improved clinical trial start up times
• NHMRC focusing on its strengths:
– Standard setter
– Broker
– Education
• Improvements can be driven by changes in behaviour; not just changes in legal regimes
Conclusions
![Page 25: Samantha Robertson - NHMRC - Improving the Australian Clinical Trials Environment](https://reader033.vdocuments.net/reader033/viewer/2022051502/58f037431a28ab764d8b45dd/html5/thumbnails/25.jpg)
• Aust CT website - www.Australianclinicaltrials.gov.au
• Twitter - @NHMRC• Twitter - @AustCT• Research Tracker - https://www.nhmrc.gov.au/media/subscription-service
• NHMRC website - https://www.nhmrc.gov.au/research/clinical-trials
Keep up to date with NHMRC Clinical Trial activities: